PepGen Ltd (PEPG) - Total Liabilities
Based on the latest financial reports, PepGen Ltd (PEPG) has total liabilities worth $26.46 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
PepGen Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how PepGen Ltd's total liabilities have evolved over time, based on quarterly financial data. See PepGen Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
PepGen Ltd Competitors by Total Liabilities
The table below lists competitors of PepGen Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Epileds Technologies Inc
TW:4956
|
Taiwan | NT$1.09 Billion |
|
MSM Malaysia Holdings Bhd
KLSE:5202
|
Malaysia | RM1.14 Billion |
|
Odlewnie Polskie SA
WAR:ODL
|
Poland | zł62.72 Million |
|
UNIBEP S.A.
WAR:UNI
|
Poland | zł1.64 Billion |
|
Moens Bank A/S
CO:MNBA
|
Denmark | Dkr4.78 Billion |
|
Value Valves Co Ltd
TWO:4580
|
Taiwan | NT$1.03 Billion |
|
Easy Field
TWO:6425
|
Taiwan | NT$1.56 Billion |
|
HMA AGRO INDUSTRIES ORD (BSE)
NSE:HMAAGRO
|
India | Rs14.50 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down PepGen Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PepGen Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 11.94 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PepGen Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PepGen Ltd (2019–2025)
The table below shows the annual total liabilities of PepGen Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $26.46 Million | -17.98% |
| 2024-12-31 | $32.26 Million | -6.84% |
| 2023-12-31 | $34.63 Million | -8.41% |
| 2022-12-31 | $37.81 Million | +258.48% |
| 2021-12-31 | $10.55 Million | +1115.09% |
| 2020-12-31 | $868.00K | +166.26% |
| 2019-12-31 | $326.00K | -- |
About PepGen Ltd
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatm… Read more